Literature DB >> 21466823

Towards the design of combination therapy for the treatment of enterovirus infections.

Hendrik Jan Thibaut1, Pieter Leyssen, Gerhard Puerstinger, Alexandra Muigg, Johan Neyts, Armando Mirko De Palma.   

Abstract

We report here on a comparative study of the activity of 10 enterovirus inhibitors against poliovirus 1, enterovirus 71 and human rhinovirus 14. Three of the selected molecules (Pleconaril, BTA-798 and V-073) are in clinical development. The in vitro antiviral activity of pairwise combinations of inhibitors indicated that most combinations resulted in an additive to slightly synergistic antiviral activity. However, the combination of ribavirin with a nucleoside polymerase inhibitor resulted in a pronounced antagonistic effect.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466823     DOI: 10.1016/j.antiviral.2011.03.187

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

1.  Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71.

Authors:  Eva Rivero-Buceta; Liang Sun; Belén Martínez-Gualda; Elisa G Doyagüez; Kim Donckers; Ernesto Quesada; María-José Camarasa; Leen Delang; Ana San-Félix; Johan Neyts; Pieter Leyssen
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 2.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

3.  An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.

Authors:  Susanne C Feil; Stephanie Hamilton; Guy Y Krippner; Bo Lin; Angela Luttick; Darryl B McConnell; Roland Nearn; Michael W Parker; Jane Ryan; Pauline C Stanislawski; Simon P Tucker; Keith G Watson; Craig J Morton
Journal:  ACS Med Chem Lett       Date:  2012-02-13       Impact factor: 4.345

4.  Fluoxetine is a potent inhibitor of coxsackievirus replication.

Authors:  Jun Zuo; Kevin K Quinn; Steve Kye; Paige Cooper; Robert Damoiseaux; Paul Krogstad
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

5.  Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.

Authors:  Rana Abdelnabi; Daryl Staveness; Katherine E Near; Paul A Wender; Leen Delang; Johan Neyts; Pieter Leyssen
Journal:  Biochem Pharmacol       Date:  2016-09-21       Impact factor: 5.858

6.  Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon.

Authors:  Yannick Debing; Suzanne U Emerson; Yijin Wang; Qiuwei Pan; Jan Balzarini; Kai Dallmeier; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

7.  The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.

Authors:  Aloys Tijsma; David Franco; Simon Tucker; Rolf Hilgenfeld; Mathy Froeyen; Pieter Leyssen; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

8.  In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71.

Authors:  Yizhuo Wang; Guiming Li; Shilin Yuan; Qianqian Gao; Ke Lan; Ralf Altmeyer; Gang Zou
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.938

Review 9.  Strategies to develop antivirals against enterovirus 71.

Authors:  Rei-Lin Kuo; Shin-Ru Shih
Journal:  Virol J       Date:  2013-01-22       Impact factor: 4.099

Review 10.  Recent developments in antiviral agents against enterovirus 71 infection.

Authors:  Chee Wah Tan; Jeffrey Kam Fatt Lai; I-Ching Sam; Yoke Fun Chan
Journal:  J Biomed Sci       Date:  2014-02-12       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.